HNSA 5487
Alternative Names: HNSA-5487Latest Information Update: 11 Oct 2023
At a glance
- Originator Hansa Biopharma AB
- Class Antineoplastics; Enzymes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Cancer
Most Recent Events
- 09 Oct 2023 Pharmacokinetics, pharmacodynamics and adverse events data from phase-I NICE-01 trial in Autoimmune disorders and Cancer (In volunteers) released by Hansa Biopharma
- 20 Jul 2023 Hansa Biopharma completes enrolment in its phase I trial for autoimmune disorders (In volunteers) in Unknown location (unspecified route)
- 20 Jul 2023 Hansa Biopharma completes enrolment in its phase I trial for cancer (In volunteers) in Unknown location (unspecified route)